EBV-positive diffuse large B-cell lymphoma in young immunocompetent individuals

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 6, 2011, Pages 512-516

  Beltran, Brady E ^a   Morales, Domingo ^a   Quiñones, Pilar ^a   Medeiros, L Jeffrey ^b   Miranda, Roberto N ^b   Castillo, Jorge J ^c  

^a HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD20 ANTIGEN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE;

ABDOMINAL PAIN; ADULT; ANTIGEN DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CASE REPORT; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLAST; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MALE; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR NECROSIS;

EID: 84860624083     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.07.003     Document Type: Article

References (27)

1. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008.
2. Armitage JO. The changing classification of non-Hodgkin's lymphomas. CA Cancer J Clin 1997; 47:323-5. (Pubitemid 27494152)
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-94.
4. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29:200-7.
5. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937-47. (Pubitemid 34651353)
6. Chen W, Houldsworth J, Olshen AB, et al. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood 2006; 107:2477-85. (Pubitemid 43345571)
7. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009; 113:3754-64.
8. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18:3707-21.
9. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008; 83:804-9.
10. Kanavaros P, Briere J, Emile JF, et al. Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Leukemia 1996; 10 (suppl 2): s84-7. (Pubitemid 126754016)
11. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 1992; 80:1804-12.
12. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991; 337:320-2.
13. Nakamura S, Jaffe ES, Swerdlow S. EBV positive diffuse large B-cell lymphoma of the elderly. In Swerdlow S, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:243-4.
14. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275-82. (Pubitemid 38029949)
15. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007; 13:5124-32. (Pubitemid 47502080)
16. Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010; 41:352-7.
17. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110:972-8. (Pubitemid 47267436)
18. Morales D, Beltran B, De Mendoza FH, et al. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma 2010; 51:66-72.
19. Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist 2011; 16:87-96.
20. Morishima S, Yamamoto K, Kimura H, et al. Increased peripheral T cell responses to EBV-infected cells with frequent detection of EBV-DNA in plasma and viral mRNA in peripheral B-cells in immunocompetent EBV-positive diffuse large B-cell lymphoma patients. Blood 2010; 116:4163 [abstract].
21. Gibson SE, Hsi ED. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 2009; 40:653-61.
22. Beltran BE, Castillo JJ, Salas R, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. Leuk Lymphoma 2011; 52:153-6.
23. Wada N, Ikeda J, Hori Y, et al. Epstein-Barr virus in diffuse large B-Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries. J Med Virol 2011; 83:317-21.
24. Merlo A, Turrini R, Bobisse S, et al. Virus-specific cytotoxic CD4 T cells for the treatment of EBV-related tumors. J Immunol 2010; 184:5895-902.
25. Zou P, Kawada J, Pesnicak L, et al. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol 2007; 81:10029-36. (Pubitemid 350067706)
26. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A 2004; 101:4960-5. (Pubitemid 38469185)
27. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109:2571-8. (Pubitemid 46425904)